Clinical Trial Update: Biological Effects of LEO 43204 in Actinic Keratosis [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the biological effects of the topical agent LEO 43204 in actinic keratosis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEO 43204

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 1 | Status: COMPLETED